Yoon Dong-min, CEO of SolarStar Ventures, "US Boston Bio Entry: Localization, Benchmarking, and Data Are Key"

Yoon Dong-min, CEO of SolarStar Ventures, stated that as more Korean bio companies enter the Boston bio cluster, the largest pharmaceutical and bio market in the world, a localization and benchmarking-focused strategy is crucial for successful local entry.

Yoon Dong-min, CEO of SolarStar Ventures, is giving a special lecture at the 'Korea University Medical Center - Yonsei University Medical Center Joint Technology Briefing' held on the afternoon of the 24th at the President Hotel in Jung-gu, Seoul.
[Photo by Lee Myung-hwan]

On the 24th, at the ‘Korea University Medical Center-Yonsei University Medical Center Joint Technology Briefing’ held at the President Hotel in Jung-gu, Yoon said in a special lecture, "By benchmarking and networking to assess the level of data and focusing on research, global expansion can be successful."

SolarStar Ventures is a venture capital (VC) firm established locally in Boston by Aju IB Investment, investing in biotech through localization strategies. According to CEO Yoon, SolarStar Ventures’ internal rate of return (IRR) reaches 25%, about 10 percentage points higher than the average IRR of 15% for local Boston VCs.

Yoon explained that many biotechs founded locally in Boston have a structure where the startup strategy and management are separated. Scientists such as professors with startup ideas take on the role of Chief Strategy Officer (CSO) only, while separate Chief Executive Officers (CEO) and Chief Financial Officers (CFO) form the company. The company then grows in scale through investments from VCs and others.

The key strategies emphasized by CEO Yoon for entering the Boston market are localization, benchmarking, and securing data. First, it is necessary to secure local personnel to build networking for investment. He said, "I have seen many cases where only personnel are sent from Korea but business networking is not properly done," adding, "It is important to recruit local personnel and form a team for networking to achieve localization."

Benchmarking big pharma is also important because it helps identify research and development (R&D) trends. Yoon said, "R&D trends change in real time," and "By observing how trends evolve, you can get hints about big pharma’s R&D trends." Securing research data to attract investment is also necessary, as data can prove the efficacy of the bio-pharmaceuticals being developed. Yoon explained, "You need to prepare data at the level global pharma companies want from the projects under development," and "If the data is good, someone will recognize its value."

Yoon evaluated that Korean bio-related scientists possess skills comparable to those of scientists from other countries. He said, "Two to three years ago, Chinese companies were very active, but due to the US-China conflict, the influence of Chinese biotechs has declined," advising, "If local networking and data are supported, Korean biotechs can definitely achieve results."

The core bio fields and therapeutic modalities Yoon foresees for this year are oncology, metabolic diseases and obesity treatments, and cell and gene therapies (CGT). This is because global big pharma and VC investments have been concentrated in these areas during the first half of this year.

Meanwhile, the event was organized to facilitate partnering for companies founded through Korea University Medical Center and Yonsei University Medical Center. Ten medical center startup companies, including NewLive, Biomi, and OncoMaster, introduced their technologies through corporate IR presentations. One-on-one meetings between companies seeking investment and investors were also arranged.

This content was produced with the assistance of AI translation services.